Advanced Health Intelligence Ltd

Advanced Health Intelligence Ltd operates as a mobile application and technology development company in Australia and internationally. It develops and patents BodyScan, a proprietary measurement/dimensioning technology that enables end-user to check and assess body dimensions using a smartphone. The company also provides FaceScan for measuring vital signs, and risks associated with cardiovascular disease, heart attack, and stroke; and DermaScan, a dermatological scanner. It serves mobile health and telehealth, life and health insurance, fitness and wellness, and consumer apparel sectors. The company was formerly known as MyFiziq Limited and changed its name to Advanced Human Imaging Limited in March 2021. Advanced Human Imaging Limited was incorporated in 2014 and is based in South Perth, Australia.

Advanced Health Intelligence Ltd trades as AHI on NASDAQ. The company is classified in Technology / Software - Application and reports in USD.

The current profile places the business in Software - Application. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $368,429 of revenue and -$4.15M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Advanced Health Intelligence Ltd can be compared against peers such as China Index Holdings Limited, CooTek (Cayman) Inc., Cyber Security 1 AB (publ), DiDi Global Inc., Moatable, Inc., Cloopen Group Holding Limited.

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $345.76M, beta of 1.61, and return on equity of -236.6%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

AHI currently shows total debt of $2.21M and beta of 1.61. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

Recent filings to review: 25-NSE (2025-08-05 00:00:00), 6-K (2025-07-15 00:00:00), 6-K (2025-02-05 00:00:00), 6-K (2024-10-28 00:00:00).

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.advancedhumanimaging.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.